KEPATUHAN MEMINUM OBAT ADJUVAN HORMONAL PADA PASIEN KANKER PAYUDARA DI RSUP DR. M. DJAMIL PADANG PADA MASA PANDEMI COVID-19
Article Sidebar
Usus,
Patogenesis,
Penyakit,
Peradangan
Main Article Content
Abstract
Latar Belakang: Beberapa studi telah menunjukkan bahwa kepatuhan menjalani terapi adjuvan hormonal oral mampu meningkatkan survival rate pada pasien kanker payudara dengan ER+ atau PR+. Munculnya pandemi COVID-19 di awal tahun 2020 dapat mempengaruhi kepatuhan pasien karena masyarakat tidak bisa beraktivitas seperti biasanya. Objektif: Tujuan penelitian adalah mengetahui kepatuhan meminum obat adjuvan hormonal pada pasien kanker payudara di RSUP Dr. M. Djamil Padang pada masa pandemi COVID-19.Metode: Penelitian merupakan studi observasional dengan desain penelitian potong-lintang (cross sectional). Studi penelitian ini diikuti oleh 75 responden. Kepatuhan dinilai menggunakan Medication Posession Rate (MPR) dan kuesioner MMAS-8 yang telah dimodifikasi. Profil sosiodemografi dan klinis responden diperoleh melalui wawancara di Poliklinik Bedah, Sub Divisi Bedah Onkologi menggunakan kuesioner terstruktur dan pengamatan rekam medis responden.Hasil: Kepatuhan pasien adalah sebesar 93.3% (70 dari 75 pasien). Hasil analisis bivariat menunjukkan faktor ekonomi memiliki hubungan signifikan dengan kepatuhan terapi. Kesimpulan: Kepatuhan meminum obat yang tinggi pada pasien kanker payudara di RSUP Dr. M. Djamil Padang dan direkomendasikan untuk memberikan perhatian lebih terhadap pasien berpendapatan rendah
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
World Health Organization (WHO). Breast cancer now most common form of cancer. 2021; Tersedia pada: https://www.who.int
Global Cancer Observatory (GCO). Indonesia Fact Sheet [Internet]. 2021. hal. 1. Tersedia pada: https://gco.iarc.fr
Indra. Sosialisasi Hari Kanker Sedunia dengan Guru SMA 1 Padang [Internet]. Dinas Kesehatan Provisni Sumatera Barat. 2020. Tersedia pada: https://dinkes.sumbarprov.go.id/details/news/467
Briani Sobri F. Terapi Sistemik Kanker Payudara dengan Reseptor Hormon Positif. In: Manajemen Terkini Kanker Payudara. edisi II 2. Sagung Seto; 2018. hal. 254.
Xu H, Jin F, Zhang X jie, Wang D qiu, Yu S fen, Wang A ping. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey. Cancer Med. 2020;9(11):3703–13.
Sisti JS, Bernstein JL, Lynch CF, Reiner AS, Mellemkjaer L, Brooks JD, et al. Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. Springerplus. 2015;4(1):1–11.
World Health Organization (WHO). Breast Cancer [Internet]. 2021. Tersedia pada: https://www.who.int
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–38.
Khambri D. Peran terapi hormonal pada kanker payudara. Maj Kedokt Andalas. 2015;38:64–73.
Ricci-Cabello I, Vásquez-Mejía A, Canelo-Aybar C, Niño De Guzman E, Pérez-Bracchiglione J, Rabassa M, et al. Adherence to breast cancer guidelines is associated with better survival outcomes: A systematic review and meta-analysis of observational studies in EU countries. BMC Health Serv Res. 2020;20(1):1–12.
Baum M, Brinkley DM, Dosset JA, McPherson K, Jackson IM, Rubens RD, et al. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer. 1988;57(6):608–11.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet [Internet]. 2013;381(9869):805–16. Tersedia pada: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/?report=reader
Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet [Internet]. 2015;386(10001):1341–52. Tersedia pada: https://pubmed.ncbi.nlm.nih.gov/26211827/
Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–8.
Budiman A, Khambri D, Bachtiar H. Affecting’s factor to medication adherence of patient with Tamoxifen after surgery. J FK Univ Andalas. 2013;2(1):20–4.
Halilintar VD, Nadjib M, Andalusia LR. Medication Adherence of Tamoxifen to Breast Cancer Patients and the Affecting’s Factors in Dharmais Cancer Hospital Jakarta. J Medicoeticolegal dan Manaj Rumah Sakit. 2020;9(2):100–9.
Farias AJ, Hansen RN, Zeliadt SB, Ornelas I, Li C, Thompson B. The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients. HHS Public Access. 2018;
Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf. 2016;25(8):953–9.
Kaleva V. Adherence to medication. Pediatriya. 2015;55(2):68–9.
Muliawan BT. Pelayanan konseling akan meningkatkan kepatuhan pasien pada terapi obat. binfar depkes [Internet]. 2008; Tersedia pada: http://www.binfar.depkes.go.id/def_menu.php
Wahyudi I. Padang resmi berstatus PPKM level III. antaranews [Internet]. 2022; Tersedia pada: https://www.antaranews.com/berita/2706269/padang-resmi-berstatus-ppkm-level-iii
Mujamil, Sety LOM, Zainuddin A, Kusnan A. Analisis Faktor Yang Berhubungan Terkait Kepatuhan Minum Obat Pasien Tuberkulosis Paru BTA+ di Masa Pandemi Covid 19 di Puskesmas Wilayah Kota Kendari. J Nurs Updat [Internet]. 2021;12(No.2). Tersedia pada: https://stikes-nhm.e-journal.id/NU/article/view/348
Soewoto W. Breast cancer patients therapeutic adherence during the COVID-19 pandemic in Indonesia. J Clin Oncol [Internet]. 1 Oktober 2021;39(28):89–89. Tersedia pada: https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.89
Utomo ARH. Memahami proses karsinogenesis kanker payudara. In: briani sobri F, Azhar Y, Wibisana IG, Rachman A, editor. Manajemen Terkini Kanker Payudara. II 2018. Sagung Seto; 2018. hal. 36–54.
Sihombing M, Sapardin AN, Penelitian B, Ri KK. Faktor Risiko Tumor Payudara pada Perempuan Umur 25-65 tahun di Lima Kelurahan Kecamatan Bogor Tengah. Kementeri Kesehat Republik Indones. 2011;
Badan Pusat Statistik (BPS). Persentase Penduduk yang Memiliki Jaminan Kesehatan Menurut Provinsi dan Jenis Jaminan, 2021 [Internet]. Meta data Subdirektorat Statistik Kesehatan dan Perumahan. 2021. Tersedia pada: https://www.bps.go.id/indikator/indikator/view_data_pub/0000/api_pub/UUROM3lMeGsxZ0czT2xFeEJsK0VWZz09/da_04/1
Zamrodah Y. Peran Ditjen Kesmas Daman Pndemi COVID 19 2020-2021. 2016;15(2):1–23.
Ali EE, Cheung KL, Lee CP, Leow JL, Yap KY, Chew L. Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore. Asia-Pacific J Oncol Nurs. 2017;4(4):283–9.
Jiang H, Dong Y, Zong W, Zhang X jie, Xu H, Jin F. The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy. BMC Womens Health [Internet]. 2022;22(1):1–11. Tersedia pada: https://doi.org/10.1186/s12905-022-01722-0
Notoatmodjo S. Metodologi penelitian kesehatan. Jakarta: Rineka Cipta; 2010.
Peltzer K, Pengpid S. Socioeconomic factors in adherence to HIV therapy in low- and middle-income countries. J Heal Popul Nutr. 2013;31(2):150–70.
Pujasari A, Setyawan H, Udiyono. Faktor – Faktor Internal Ketidakpatuhan Pengobatan Hipertensi Di Puskesmas Kedungmundu Kota Semarang. J Kesehat Masy [Internet]. 2015;3(3):99–108. Tersedia pada: http://www.tjyybjb.ac.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=9987
Guan WJ, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;
Fontein DBY, Nortier JWR, Liefers GJ, Putter H, Meershoek-Klein Kranenbarg E, van den Bosch J, et al. High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Eur J Surg Oncol [Internet]. Februari 2012;38(2):110–7. Tersedia pada: https://linkinghub.elsevier.com/retrieve/pii/S0748798311006986
Yussof I, Mohd Tahir NA, Hatah E, Mohamed Shah N. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review. The Breast [Internet]. April 2022;62:22–35. Tersedia pada: https://linkinghub.elsevier.com/retrieve/pii/S0960977622000121
Jimmy B, Jose J. Patient Medication Adherence: Measures in Daily Practice. Oman Med J [Internet]. Mei 2011;26(3):155–9. Tersedia pada: http://www.omjournal.org/fultext_PDF.aspx?DetailsID=93&type=fultext
Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer [Internet]. September 2006;42(14):2271–6. Tersedia pada: https://linkinghub.elsevier.com/retrieve/pii/S0959804906002097
Irwin M. Theoretical Foundations of Adherence Behaviors. Clin J Oncol Nurs [Internet]. 1 Juni 2015;19(3):31–5. Tersedia pada: http://cjon.ons.org/cjon/19/3/supplement/theoretical-foundations-adherence-behaviors-synthesis-and-application-adherence